報價延遲最少15分鐘:2026/03/09 10:57 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.015 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.05/-3.11
|
|
企業價值
1.61B
|
| 資產負債 |
|
每股賬面淨值
5.24
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
83.98M
|
|
每股收益
0.67
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment. |
